Replimune Group, Inc. (REPL)
Develops viruses engineered to attack cancer by activating the immune system.
$5.34-0.38%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-29.8%
The outlook
REPL trades at $5.34, well below both its 50- and 200-day moving averages, placing it in the lower portion of its 52-week range. Analyst consensus leans toward Hold, with an average price target roughly double the current price—a notable gap that reflects mixed conviction across the six analysts covering the stock. Overall sentiment is neutral, balancing the depressed technical position against the substantial upside embedded in consensus targets.
What’s behind the score
Analyst consensusHold — 2.9 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range35% of the way from its 52-week low to high
Price targetAvg target +100% vs current price
Analyst price target
~12-month · 6 analysts$10.67average target+99.8% vs now
Now $5.34
Low $2.00High $17.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$448.3M
52-wk high
$12.50
52-wk low
$1.50
50-day avg
$9.11
200-day avg
$7.78
Trailing P/E
—